Topic: off-label marketing
Texas spanked AstraZeneca as a repeat offender in announcing a pair of off-label marketing settlements.
A former Biogen sales manager has sued the company claiming she was let go after she filed a corporate integrity complaint.
The feds charged five doctors over accepting Insys' bribes and said they've secured cooperation from two former employees.
Aegerion admitted in court that it touted its cholesterol med Juxtapid for patients with a disease it wasn't approved to treat.
A federal judge rebuffed Aegerion's proposed $36M marketing settlement, saying it highlights a "two-tier criminal justice system."
Federal agents arrested Insys founder John Kapoor and charged him with racketeering and other felonies.
A recent investigation alleges that Avanir Pharmaceuticals inappropriately marketed its neurological treatment Nuedexta to nursing home residents.
Aegerion Pharmaceuticals will shell out $36 million to resolve claims that it marketed Juxtapid for use beyond its FDA approval.
Celgene will pay $280 million to settle an off-label marketing case it has fought for years; it's among the larger recent whistleblower deals.
Beleaguered Insys faces yet another legal challenge with Anthem's decision to take the opioid drugmaker to court.